The Garvan Institute’s TenK10K project aims to map 50 million human cells from 10,000 individuals.
PLEASANTON, California., Aug 5th 2024 /PRNewswire/ — 10x Genomics, Inc. (Nasdaq: TXG), a leader in the single cell and biologics space, announced today its participation in TenK10K, a large, multi-year study led by the Garvan Institute of Medical Research. The TenK10K project plans to map 50 million human cells from 10,000 individuals to identify unique genomic fingerprints of autoimmune diseases, heart disease and cancer. For this important project, the Garvan Institute has selected Chromium GEM-X products to generate single-cell data to improve the accuracy of predicting disease risk and treatment response.
“TenK10K has the potential to make a significant step forward in personalized medicine,” said Prof. Joseph Powell, TenK10K project leader, Program Director for Translational Genomics at the Garvan Center for Medical Research, and Director of the UNSW Cellular Genomics Futures Centre. “With single-cell sequencing, which examines individual cells rather than the average of many cells, we are able to see fingerprints that we have previously been able to identify. We are excited about the translational possibilities that come from combine these leading sequencing and single-cell technologies with advanced machine learning techniques.”
One of the largest projects of its kind, TenK10K aims to improve the identification and development of disease-related cell fingerprints:
- Commercial trials to find effective treatments for challenging autoimmune diseases including multiple sclerosis, rheumatoid arthritis, lupus, type 1 diabetes, spondylitis, inflammatory bowel disease and Crohn’s disease.
- Early trials of new potent RNA therapies
- Potential early targets for cancer treatment and long-term COVID
- Trials to track the effects of heart disease and to determine the risk of sudden death
As part of this new study, the Garvan Center will use Chromium GEM-X products, the next generation of single-cell 10x Genomics technology, to provide more understanding, more, the quality of the data and sample recovery. GEM-X is uniquely positioned for translational research, offering class-leading performance at greater scale and at lower cost, even with more complex samples.
“Single cell analysis on a large scale has the potential to have a major impact on the way we understand, diagnose, treat and ultimately cure disease. We are excited to see the Garvan Institute help to turn this potential into reality and use our new Chromium GEM-X Technology as part of their TenK10K core project,” said Ben Hindson, Co-Founder and Chief Scientific Officer at 10x Genomics. “Enabling more researchers to harness the full power of high-throughput single-cell analysis at greater scale and lower cost is what drives our continued pace of innovation.”
TenK10K builds on the early success of the Garvan Institute’s pioneering OneK1K study. For the 2022 paper published on Science, Powell and a team of researchers used single-cell sequencing technology from 10x Genomics to examine the genomic profile of more than a million cells from 1,000 individuals. This study led to a proof-of-principle trial in 10 hospitals Sydney, Australia to help match individual patients with the most effective treatment.
“Preliminary results suggest that we can predict a patient’s response to treatment based on their genetic makeup,” Powell added.
For the TenK10K project, the Garvan Institute partnered with Illumina, which provides donations, equipment and special research support to the Garvan Institute.
About 10x Genomics
10x Genomics is a life sciences company that builds products to accelerate biological breakthroughs and advance human health. Our integrated solutions include tools, equipment and software for single cell and spatial biology, helping academic and translational researchers and biopharmaceutical companies to understand biological processes with greater resolution and scale. compatible with biological complexity. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are changing the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or contact us LinkedIn or X (Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities The Exchange Act of 1934, as amended, falls under the “safe harbor” of those sections. All statements, other than statements of historical fact, may be forward-looking statements. Forward-looking statements can generally be identified by the use of forward-looking words such as “may,” “probably,” “will,” “should,” “expect,” “plan,” “anticipate,” “may occur,” “intend,” “goal,” “project,” “consider,” “believe,” “estimate,” “predict,” “likely” or “proceed” or variations thereof or similar terms , but the absence of these words does not mean that the sentence is not forward looking. These forward-looking statements include statements about 10x Genomics, Inc.’s products, operations, configuration, capabilities, uses and anticipated plans using 10x Genomics technology. These statements are based on management’s current expectations, estimates, beliefs, assumptions and information available to management, and actual results and outcomes may differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics’ financial results and operations and cause actual results to differ materially from those suggested by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (“SEC”) from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct and cannot guarantee that actual results will be accurate. upcoming, operating conditions, performance, usage and events and conditions. indicated in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements made to reflect any change in its expectations or any change in the events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing the views of 10x Genomics as of any date after the date of this press release.
Disclosure Information
10x Genomics files with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as a means of disclosing non-public information and complying with our disclosure obligations under Regulation FD.
Names
Investors: [email protected]
Media: [email protected]
SOURCE 10x Genomics, Inc.
#10x #Genomics #Technology #Supports #TenK10K #Project #Led #Garvan #Institute #Medical #Research #Transform #Cancer #Treatment